摘要

VESALIUS-CVA randomized controlled trial enrolling 12,257 adults with high-risk diabetes or atherosclerosis but no prior myocardial infarction or stroke, assigned to evolocumab 140 mg every two weeks or placebo on top of optimized lipid-lowering therapy. Over a median 4.6 years it showed a 25% reduction in three-point MACE and a 36% reduction in first myocardial infarction. randomized 12,257 patients with 动脉粥样硬化动脉粥样硬化是导致大多数心脏病发作和许多中风的疾病。胆固醇颗粒卡在动脉壁内，身体派出免疫细胞进行清理，经过多年，这些杂质硬化成斑块。. or high-risk 糖尿病糖尿病是一种血糖持续过高的疾病，其原因要么是身体产生的胰岛素太少，要么是身体对自身产生的胰岛素停止产生反应。. but no previous 心肌梗死请参阅“心脏病发作”以获取完整条目。. 或 中风当大脑某一部分的血液供应因血管阻塞或出血而中断时，就会发生中风。. 到 依洛尤单抗依洛尤单抗是一种属于PCSK9抑制剂类别的注射用降胆固醇药物，通常每两到四周给药一次。. 140 mg every two weeks or 安慰剂安慰剂是一种假治疗手段——比如糖丸或生理盐水注射——其目的是让研究人员能够确定真实药物的实际疗效。., added to optimized lipid-lowering therapy [1]. Over a median 4.6 years, evolocumab reduced three-point MACE by 25% and four-point MACE by 19%, and reduced first myocardial infarction by 36% [1]. In the prespecified subgroup with diabetes and no known significant atherosclerosis, both primary endpoints fell by 31% [2]. This paper places that result inside the wider primary-prevention evidence base, from WOSCOPSThe West of Scotland Coronary Prevention Study, a 1995 randomized trial of pravastatin versus placebo in approximately 6,595 middle-aged men with elevated LDL cholesterol and no prior myocardial infarction. It was one of the first large trials to demonstrate that cholesterol lowering prevents heart attacks in people who have not yet had one. through 木星JUPITER 试验在胆固醇正常但 CRP 升高（提示隐匿性炎症）的人群中测试了一种他汀类药物。., HOPE-3, EWTOPIA 75A Japanese randomized open-label trial of ezetimibe monotherapy versus dietary counseling alone in approximately 3,796 adults aged 75 and older with LDL-C of at least 140 mg/dL and no history of coronary artery disease. It showed a 34% relative reduction in atherosclerotic cardiovascular events over five years. 和 胆固醇胆固醇是身体所需的一种蜡状物质。它存在于细胞壁、荷尔蒙、维生素D以及消化食物的胆汁中。没有它，你就会死亡。. Treatment Trialists analyses, and examines the proposition that these trials are acting on a common quantity: the concentration of 载脂蛋白载脂蛋白是附着在你血液中脂质运载颗粒上的一种蛋白质。由于脂肪和水不相溶，这些蛋白质就像一层包装，让脂肪能够在血液中安全地运输。. B (载脂蛋白B载脂蛋白B（ApoB）是一种存在于每个可能卡在动脉壁并导致斑块形成的胆固醇颗粒外侧的蛋白质。其中每一个颗粒都恰好携带一个ApoB。.) particles available for arterial retention, integrated over time. I set out the arithmetic connecting apoB to 低密度脂蛋白胆固醇低密度脂蛋白胆固醇，简称LDL-C，是指存在于低密度脂蛋白颗粒内部的胆固醇量。它是几乎每份标准实验室化验报告上都会显示的数据。., explain why the two measures diverge and what follows when they do, give context-dependent reference values, and address two practical questions — whether evolocumab outperforms a 他汀他汀类药物可减缓肝脏用于制造胆固醇的酶的活性。作为回应，肝脏会从血液中清除更多的胆固醇，这正是真正益处所在。., and what it adds when a statin is already in place. The defensible conclusion is narrower than the headlines: intensive PCSK9-mediated lowering can prevent first events in selected high-risk patients, but the trial does not establish routine treatment in average-risk 一级预防一级预防是指对从未发生过心脏病发作或中风的人进行治疗，以防止首次发作。., does not establish monotherapy effectiveness, and does not validate a quantitative “载脂蛋白B年ApoB-years（载脂蛋白B年）是一个提出的研究指标，表示随时间推移累积的载脂蛋白B暴露量，以mg/dL·年为单位，即ApoB对年龄曲线下的面积；旨在比任何单次测量更直接地捕捉综合致动脉粥样硬化颗粒负荷，但尚未被验证为临床工具或治疗阈值。.” treatment algorithm.

1. Why This Trial Changes the Question

For thirty years the debate about 降脂降低血脂是指通过饮食、药物或两者结合，减少血液中携带载脂蛋白B（ApoB）的有害颗粒。. in people who have never had an event has been a debate about thresholds: how high does risk have to be before treatment is worth it? VESALIUS-CV does not settle that question, but it moves it. It was the first cardiovascular outcomes trial to show that adding a PCSK9 抑制剂PCSK9抑制剂是一种能够阻断这种降胆固醇蛋白的药物，从而腾出更多的结合位点，以清除血液中的胆固醇颗粒。. to optimized lipid-lowering therapy reduced major cardiovascular events in high-risk patients without prior myocardial infarction or stroke [1].

That is a narrower claim than “the first non-statin to work in primary prevention,” and the narrower claim is the correct one. EWTOPIA 75 had already shown that 依折麦布依折麦布是一种阻止肠道吸收胆固醇的药丸。. monotherapy reduced atherosclerotic cardiovascular events in Japanese patients aged 75 and older with LDL-C of at least 140 mg/dL and no history of coronary disease, although that trial was open-label with dietary counseling as the comparator [18].

What VESALIUS-CV contributes is not a new mechanism. It is confirmation of an established one in a population where it had not been tested with a PCSK9PCSK9 是由您的肝脏制造的一种蛋白质，它会破坏肝脏用于将胆固醇从血液中清除的对接位点。. inhibitor, at an effect size close to what the statin literature predicts for the same magnitude of LDL-C reduction [1,19].

2. What VESALIUS-CV Actually Tested

The trial enrolled 12,257 patients at 774 sites in 33 countries [1]. Median age was 66 years, 43% were women, 93% were White, and median follow-up was 4.6 years. Entry required an LDL-C of at least 90 mg/dL, non-HDL-C of at least 120 mg/dL, or apoB of at least 80 mg/dL, on at least two weeks of optimized therapy. Baseline median LDL-C was approximately 122 mg/dL and apoB approximately 102 mg/dL; approximately 87% were receiving a statin, 68% a 高强度他汀类药物高强度他汀类药物是指预计能将低密度脂蛋白降低50%或更多的剂量——在实践中，即较高剂量的阿托伐他汀或瑞舒伐他汀。., and about 19% ezetimibe [1].

The population ranged from patients with established atherosclerosis or prior PCI — but no previous myocardial infarction or stroke — to patients with high-risk diabetes and no documented significant atherosclerosis. Two-thirds had documented atherosclerosis (45% coronary, 17% peripheral, 10% cerebrovascular) and 59% had diabetes [1]. Participants in the latter group were classified as having no known significant atherosclerosis; they were not systematically imaged in a way that would establish that 斑块斑块是胆固醇、免疫细胞、瘢痕组织和钙质在动脉壁内部的沉积。. was absent [2].

At 48 weeks, evolocumab reduced LDL-C by roughly 55% (45 vs 109 mg/dL), non-HDL-C by 47%, and apoB by 44% [1]. Lp(a) fell by about 27% [5].

Outcome at 5 years	依洛尤单抗	Placebo	Effect	Absolute benefit
CHD death, MI, or 缺血性卒中缺血性中风是指流向部分大脑的血液受阻，导致脑组织开始坏死。. (3-P MACE)	6.2%	8.0%	HR 0.75 (95% CI 0.65–0.86)	1.8%; NNT ≈ 56
3-P MACE + ischemia-driven 血运重建血运重建术是一种医疗或外科手术（例如冠状动脉旁路移植术或经皮冠状动脉介入治疗），旨在恢复通过阻塞或狭窄的冠状动脉的血流，解决的是物理性阻塞，而不是潜在的动脉粥样硬化病变过程。. (4-P)	13.4%	16.2%	HR 0.81 (95% CI 0.73–0.89)	2.8%; NNT ≈ 36
心肌梗死	2.7%	4.1%	HR 0.64	1.4%; NNT ≈ 71
All-cause death	7.9%	9.7%	HR 0.80	Exploratory

Table 1. Primary and selected secondary outcomes, VESALIUS-CV [1,6]. Mortality fell outside the hierarchical testingA pre-specified statistical strategy in clinical trials in which secondary and exploratory endpoints are tested in a fixed order, and an endpoint can be declared statistically significant only if all preceding endpoints in the sequence also reached significance. In VESALIUS-CV, all-cause mortality was exploratory because coronary death did not reach significance before it in the hierarchy. sequence because coronary death did not reach significance ahead of it; the 20% relative reduction is hypothesis-generating rather than confirmatory.

2.1 Counting every event, not just the first

A prespecified cumulative-events analysis counted recurrent as well as first events [3]. Across follow-up there were 1,654 first four-point MACE events and a further 1,107 subsequent events — 2,761 in total, roughly two-thirds more event burden than a conventional time-to-first-event analysis registers. Evolocumab reduced first events by 19%, subsequent events by about 25%, and total events by 20%, preventing approximately 55 first or subsequent events per 1,000 patients treated for five years. For the three-point composite the total-event reduction was 27% [3].

This bears on how prevention should be valued. A first infarction is often a transition into a higher-risk state rather than a terminal endpoint, and analyses that stop counting at the first event understate the burden that treatment averts [3].

2.2 The subgroup without known significant atherosclerosis

The clearest primary-prevention signal comes from the prespecified subgroup of 3,655 patients with diabetes and no known significant atherosclerosis — defined as no prior arterial revascularization, no 狭窄狭窄是指管腔变窄，通常以百分比来描述，例如百分之七十的阻塞。. of 50% or more, and no 冠状动脉钙化积分冠状动脉钙化积分（简称CAC积分）通过快速CT扫描测定心脏动脉中硬化斑块的含量。无需造影剂，无需扎针，大约需要十分钟。. of 100 阿特斯通单位阿加特森单位是用于量化CT扫描中冠状动脉钙化的标准化评分单位，根据钙化病变的密度 and 面积计算得出；零分表示未检测到钙化斑块，而300分或更高（仅在英国大师研究的运动员组中发现）则反映了重度钙化。. or higher [2]. Median age was 65 years and 57% were women. At 48 weeks, LDL-C was 52 mg/dL with evolocumab versus 111 mg/dL with placebo.

• Three-point MACE: 5.0% vs 7.1% (HR 0.69; 95% CI 0.52–0.91; P = .009). Five-year NNT ≈ 48 [2].
• Four-point MACE: 7.6% vs 10.5% (HR 0.69). Five-year NNT ≈ 35 [2].
• Cardiovascular death HR 0.68 (95% CI 0.46–0.99); all-cause death HR 0.76 (95% CI 0.61–0.95). Both exploratory given the hierarchical testing order [2].
• Event-curve separation was more apparent after the first year, with 41% (3-P) and 39% (4-P) reductions in the years that followed [2].

That temporal pattern is consistent with, but does not prove, a slower emergence of benefit when baseline 斑块负荷斑块负荷是指动脉中所有斑块的总量，遍布全身——而不仅仅是最严重的单一病灶处。. is lower. A landmark analysis can describe when curves separate; it cannot establish plaque burden or mechanism. If the interpretation is correct, it carries a practical implication — that fixed-duration primary-prevention trials are structurally conservative — but that implication rests on the interpretation, not on the data alone.

3. The Primary-Prevention Evidence That Came Before

VESALIUS-CV did not arrive in a vacuum. Several trials had already tested lipid lowering in people without established coronary disease, and the pattern across them is consistent enough to be worth tabulating.

Trial (year)	人口	养生方案	LDL-C lowering	Primary result
WOSCOPS (1995) [11]	6,595 men, LDL-C ~192 mg/dL, no prior MI	普伐他汀一种中等强度的他汀类药物，在常规批准剂量范围内可将低密度脂蛋白胆固醇（LDL-C）降低约22–32%；由于其不通过CYP3A4途径代谢且具有亲水性，因此在担心肌肉耐受性问题时，通常更倾向于选用该药物。. 40 mg	26% (~48 mg/dL)	Nonfatal MI or CHD death 7.9% → 5.5%; 31% RRR over 4.9 y
AFCAPS/TexCAPS (1998) [13]	6,605 with average lipids, low HDL-C	Lovastatin 20–40 mg	25%	First acute major coronary event RR 0.63 over 5.2 y
ASCOT-LLA (2003) [14]	10,305 hypertensive with ≥3 风险因素危险因素是指会增加您患病几率的因素——例如高胆固醇颗粒、高血压、吸烟、糖尿病、家族病史。.	阿托伐他汀阿托伐他汀（商品名立普妥）是效力最强的两种他汀类药物之一，也是世界上处方量最多的药物之一。. 10 mg	~35 mg/dL	Nonfatal MI + fatal CHD HR 0.64; stopped early at 3.3 y
CARDS (2004) [15]	2,838 with type 2 diabetes, no ASCVD	Atorvastatin 10 mg	~46 mg/dL	Major CV events HR 0.63 over 3.9 y
JUPITER (2008) [16]	17,802 with LDL-C <130, hsCRP ≥2 mg/L	瑞舒伐他汀瑞舒伐他汀以可定（Crestor）之名销售，是目前最强效的他汀类药物，主要停留在肝脏中，而不会在全身扩散。. 20 mg	108 → 55 mg/dL	Composite HR 0.56; stopped at 1.9 y median
HOPE-3 (2016) [17]	12,705 at intermediate risk, unselected lipids	Rosuvastatin 10 mg	26.5 mg/dL	Co-primary HR 0.76 over 5.6 y
EWTOPIA 75 (2019) [18]	3,796 Japanese adults ≥75 y, LDL-C ≥140, no CAD	Ezetimibe 10 mg monotherapy (open-label)	161 → 120 mg/dL	Composite ASCVD events HR 0.66 over 5 y
VESALIUS-CV (2026) [1]	12,257 with atherosclerosis or high-risk diabetes, no prior MI/stroke	Evolocumab 140 mg q2w added to optimized therapy; ~87% on a statin	~63 mg/dL	3-P MACE HR 0.75; 4-P HR 0.81 over 4.6 y

Table 2. Trials of lipid lowering in populations without prior myocardial infarction. Values are approximate and drawn from the primary publications; endpoint definitions differ between trials and are not strictly interchangeable.

Two structural features emerge. First, relative benefit per unit of LDL-C removed is at least as large in primary prevention as in 二级预防二级预防是对已经发生过心脏病发作、中风或安放过支架的患者进行治疗，以阻止下一次发作。.. The Cholesterol Treatment Trialists’ 2012 individual-participant 元分析Meta分析通过统计学方法将许多独立研究的结果合并为一个总体估计值。. of 27 trials reported rate ratios per 1.0 mmol/L (38.7 mg/dL) of 0.62 and 0.69 in the two lowest baseline-risk categories — roughly 38% and 31% reductions — against 0.79 to 0.81 in the higher-risk categories [9]. Restricted to participants without prior ASCVD, the overall rate ratio was 0.75 versus 0.80 in those with prior ASCVD, and the corresponding reductions in the two lowest risk strata were 39% and 34% [9,38]. One possible interpretation is that earlier lipid lowering acts before advanced plaque develops, although differences between risk strata cannot establish this mechanism.

Second, absolute benefit is smaller, because the untreated event rate is smaller. In people with a five-year major-vascular-event risk below 10%, each 1.0 mmol/L of LDL-C reduction prevented about 11 events per 1,000 treated over five years [9]. The absolute benefit was smaller than in higher-risk or post-event populations because baseline event risk was lower; its precise magnitude depends on the population and the endpoint definition. Every design decision in primary prevention is therefore a decision about how to raise the absolute yield: enrich the population by 炎症炎症是免疫系统对损伤或被视为入侵物的物质所做出的反应。它会带来肿胀、发热和清理细胞。. (JUPITER) [16], by diabetes (CARDS, and the VESALIUS-CV diabetes stratum) [15,2], by imaging-detected plaque, or — the option trials cannot test — by extending the treatment horizon from five years to fifty.

4. Standardizing Across Trials: Effect per 38.7 mg/dL

Trials with different drugs, durations, and endpoints become roughly comparable when their results are expressed per unit of LDL-C lowered. An approximate rate ratio per 1 mmol/L can be calculated as H raised to the power 1/D, where H is the observed 风险比风险比用于比较两组事件发生的速度。0.75 的比率意味着治疗组的事件发生率是对照组的三分之四。. and D the mean LDL-C difference in mmol/L, assuming a log-linear exposure-response relationship. This standardization does not eliminate differences in follow-up duration, population risk, background treatment, or endpoint definition, and should be read as an ordering device rather than an adjusted estimate.

Applied to VESALIUS-CV, the 63 mg/dL difference is about 1.63 mmol/L, so a hazard ratio of 0.75 for three-point MACE corresponds to roughly 0.84 per mmol/L, and 0.81 for four-point MACE to roughly 0.88 [1]. These values are numerically weaker than the CTT benchmark of 0.75–0.80. Differences in follow-up duration, endpoint composition, population characteristics, and background therapy may contribute, but cross-trial comparisons cannot establish the explanation. When the investigators compared observed reductions with those predicted from statin trials on the basis of LDL-C reduction alone, agreement was closer: approximately 35% observed versus 31% predicted for major coronary events, and 27% versus 29% for major vascular events [1].

Meta-regression has found broadly similar 相对危险度相对风险比较了两个组：与那一组相比，这一组的心脏病发作率低30%。. reductions per mmol/L of LDL-C lowering for statins and for established non-statin therapies acting through LDL-receptor upregulation [19]. This supports, but does not prove, a shared lipid-mediated mechanism. The practical reading is that there is no strong evidence of an evolocumab-specific or statin-specific effect beyond the 脂蛋白脂蛋白是一种微小的颗粒，负责在血液中输送脂肪和胆固醇。由于脂肪不溶于水，它需要蛋白质外壳包裹才能在血液中运输。. reduction each achieves.

5. How ApoB and LDL-C Relate to MACE

5.1 The particle as the unit of exposure

Every low-density lipoprotein, intermediate-density lipoprotein, 极低密度脂蛋白VLDL，即极低密度脂蛋白，是肝脏合成并向全身输送甘油三酯的颗粒。. remnant, and 脂蛋白(a)脂蛋白(a)，写作 Lp(a)，读作"L-P-小-a"，是一种带有额外粘性蛋白质的类 LDL 颗粒。. particle carries one molecule of apolipoprotein B-100. Chylomicrons乳糜微粒是一种极大的颗粒，它将餐后脂肪从肠道输送到血液中。. and their remnants carry 载脂蛋白B-48ApoB-48 是载脂蛋白 B 的一种截短同工 isoform，在肠道中产生，专一性地存在于乳糜微粒及其残余颗粒上；与 ApoB-100 不同，它在空腹状态下不会被标准临床 ApoB 检测所测得，这意味着常规的 ApoB 检测反映的是来自肝脏的脂蛋白所带来的致动脉粥样硬化颗粒负荷，而不是饮食脂肪的吸收。., which contributes a small fraction of total apoB in the fasting state. Total plasma apoB therefore approximates a count of 致动脉粥样硬化颗粒致动脉粥样硬化颗粒是指含ApoB的脂蛋白——包括LDL、IDL、VLDL和脂蛋白(a)——它们能够进入并滞留在动脉壁中，从而引发并维持斑块的生长；文章用该术语来描述必须大幅且持续降低以实现斑块逆转的物质。., expressed as 蛋白质蛋白质是身体用于构建和修复肌肉与组织的营养素。. mass [24,33].

低密度脂蛋白低密度脂蛋白（LDL）是将胆固醇输送至全身血液的主要颗粒，也是积聚在动脉壁上的主要颗粒。. cholesterol is a different quantity: the mass of cholesterol carried within the LDL fraction. Because cholesterol content per particle varies between individuals, the same LDL-C can correspond to meaningfully different particle counts [26].

The mechanistic relevance is that the initiating step in 动脉粥样硬化发生动脉粥样硬化形成是斑块形成的逐步过程。. is a particle-level event. Particles cross the 内皮内皮是每条血管内侧极薄、光滑的内膜。它只有单细胞厚。. at a rate related to their plasma concentration; in the 内皮下间隙内皮下间隙是动脉内膜正下方的一个狭窄间隙，位于单层细胞与下方的肌肉之间。., interactions between positively charged regions of 载脂蛋白B-100ApoB-100是存在于LDL、VLDL、IDL和残粒脂蛋白上的全长载脂蛋白B；其带正电荷的氨基酸结构域与动脉壁中带负电荷的蛋白聚糖侧链发生离子结合，从而将颗粒物理性地 atrap（截留）在内膜中并启动斑块形成。. and negatively charged arterial proteoglycans are central to retention, although retention also varies with particle size, composition, and other particle characteristics [24]. Retained particles are oxidatively modified, taken up by 巨噬细胞巨噬细胞是一种吞噬细胞碎片和入侵者的庞大免疫细胞。这个名字的字面意思是"大食客"。", and converted into 泡沫细胞泡沫细胞是一种免疫细胞，它吞噬了大量被捕获的胆固醇，导致其膨胀并在显微镜下呈现出泡沫状。., initiating the inflammatory sequence that produces a 坏死核心坏死核心是晚期斑块的坏死、糜烂中心，由吞噬了被困胆固醇随后在原地死亡的免疫细胞组成。. and, over time, rupture-prone plaque. The 保留反应模型滞留反应学说认为，动脉粥样硬化的发生始于含ApoB的脂蛋白穿过内皮屏障并被动脉内膜中的蛋白聚糖截留，从而引发氧化修饰、免疫细胞募集、泡沫细胞形成以及最终的斑块发展。., formalized in the European Atherosclerosis Society consensus statements, therefore predicts that risk should track particle number closely [22,24].

Genetic and observational evidence supports this. In multivariable 孟德尔随机化孟德尔随机化是一种巧妙的研究方法，它利用人们天生携带的基因作为自然实验。., apoB retained a robust association with coronary disease after conditioning on LDL-C and 甘油三酯甘油三酯是你血液中以及身体储存脂肪的主要形式。., while the independent association of LDL-C did not persist — though the authors cautioned that high correlation among lipid traits prevents an exclusive causal attribution to apoB [25]. In genetic analyses comparing LDL-receptor variants with lipoprotein-lipase variants, association with coronary risk tracked the absolute change in apoB regardless of which lipid fraction the variant primarily altered [23]. In statin-treated participants in the 哥本哈根一般人群研究一项规模非常庞大的丹麦研究，对数万人的脂质（包括脂蛋白(a)和残余胆固醇）进行了测量，并对其健康状况进行了多年的追踪。., apoB and non-HDL-C identified residual myocardial infarction risk that LDL-C did not [27]. And in 英国生物样本库英国生物样本库（UK Biobank）拥有五十万名英国志愿者的详细基因、生活方式和健康数据，这些数据与他们的医疗记录相连。. combined with 傅里叶FOURIER试验在已经患有心血管疾病且正在服用他汀类药物的患者中评估了PCSK9抑制剂依洛尤单抗。. 以及 IMPROVE-ITIMPROVE-IT 研究在心脏病发作后于他汀类药物的基础上加用了依折麦布，旨在测试通过非他汀机制降低低密度脂蛋白（LDL）是否有助于改善病情。., apoB carried the risk signal while LDL-C and triglycerides added little once apoB was in the model [28].

The reasonable summary is not that LDL-C is wrong. It is that LDL-C may underestimate atherogenic 颗粒物负荷颗粒负荷是指循环血浆中致动脉粥样硬化脂蛋白颗粒的总数，最好通过ApoB来测量；它与胆固醇质量不同，因为正是颗粒的物理数量——而不是它们所携带的胆固醇量——决定了脂蛋白渗入并滞留在动脉壁中的频率。. in clinically important groups, including patients with diabetes, 胰岛素抵抗胰岛素抵抗是指您的细胞对胰岛素的反应变差，因此您的胰腺必须分泌越来越多的胰岛素来完成相同的工作。., elevated triglycerides, statin treatment, or very low achieved LDL-C [26,33].

5.2 The numbers, side by side

Population-median correspondence between LDL-C and apoB, from 12,688 statin-free NHANES participants, gives the practical translation table [26]:

低密度脂蛋白胆固醇 (mg/dL)	Median apoB (mg/dL)	95% apoB range at that LDL-C	解释
55	49	—	Ratio approaches 1:1 at low LDL-C
70	60	—	An LDL-C of 70 corresponds to a population-median apoB near 60, not 80 — conventional guideline pairings are not percentile-equivalent
100	80	66–99	Half the population falls between 75 and 86 mg/dL; the outer 5% span a 33 mg/dL range
190	140	—	Ratio widens as particles become cholesterol-enriched

Table 3. Population-median apoB across the LDL-C spectrum (NHANES 2005–2016, statin-free adults, Martin-Hopkins LDL-C) [26]. Variability was greatest when LDL-C was estimated by Friedewald, lower with Sampson or Martin-Hopkins, and lowest for non-HDL-C.

Points that follow from this:

• At typical levels, apoB (mg/dL) is roughly 0.8 × LDL-C (mg/dL); at very low LDL-C the ratio approaches 1.0 [26].
• Because each atherogenic particle generally contains one apoB molecule, apoB approximates particle concentration. Using the theoretical molecular-mass conversion, an apoB of 100 mg/dL corresponds to approximately 1,820–1,950 nmol/L, or on the order of 1.1–1.2 × 10¹⁸ particles per litre; the range reflects published molecular-mass estimates for apoB-100 of roughly 512–550 kDa. This conversion is approximate and is not ordinarily required for clinical interpretation.
• 不和谐请参见 ApoB 不一致性 以获取完整条目。. reflects variation in cholesterol mass per apoB-containing particle and in the distribution of particles among LDL, remnants, and Lp(a). An exact cholesterol-molecules-per-particle value cannot be calculated from routine LDL-C and total apoB measurements alone.
• Discordantly high apoB — more particles than the LDL-C implies — is associated with elevated triglycerides, diabetes, higher HbA1c, 肥胖肥胖是指体内脂肪过多，从而影响健康。., older age, and statin use [26]. Statins lower LDL-C proportionally more than apoB, so a patient at goal on LDL-C may not be at goal on particle number [33].

5.3 Why apoB is measured differently

LDL-C is, in most laboratories, not measured directly. It is calculated from 总胆固醇总胆固醇将您所有颗粒中的胆固醇加在一起，无论有害还是有益。., HDL-C, and triglycerides using the Friedewald, Martin-Hopkins, or Sampson equations. Each makes assumptions about VLDL composition that degrade at high triglycerides and at low LDL-C — the two conditions under which treatment decisions are hardest [26].

ApoB is measured directly, by immunoturbidimetric or nephelometric immunoassay, standardized against the WHO/IFCC SP3-07 reference material. It does not require fasting and is measured directly, avoiding the triglyceride-dependent calculation errors that can affect estimated LDL-C, although apoB assays remain subject to analytical variation — typically a coefficient of variation on the order of 3–5% [33]. The reported value is a protein mass concentration; given the one-apoB-per-particle stoichiometry, it functions as a particle-count surrogate.

The trade-offs are incomplete reimbursement, inter-laboratory variation in reference ranges, and limited clinical familiarity with the values. The 2026 ACC/AHA multisociety dyslipidemia guidelineA joint clinical practice guideline from the American Heart Association and American College of Cardiology that, among other recommendations, tabulates estimated ASCVD relative-risk increments at Lp(a) concentrations from 50 to 180 mg/dL, derived from UK Biobank modeling. addresses this by recommending apoB selectively rather than universally: to improve risk assessment, to help diagnose specific lipoprotein disorders, and once LDL-C and non-HDL-C goals have been met — particularly with triglycerides above 200 mg/dL, in diabetes, or at an achieved LDL-C below 70 mg/dL [32].

6. Reference Values: Thresholds, Not Grades

It is tempting to 年级GRADE（推荐分级、评估、发展与评价）是一个广泛使用的框架，用于评定临床发现背后证据的确定性，根据研究设计、偏倚风险、一致性、直接性和结果精确度等因素，将其划分为高、中、低或极低。. lipid values as good, better, and excellent. That framing conflates three different things: guideline treatment goals, population percentiles, and speculative lifetime targets. The defensible presentation separates goals from the thresholds at which intensification is considered, and treats them as context-dependent rather than universal.

Risk context	LDL-C goal	Non-HDL-C goal	ApoB threshold supporting intensification
Borderline or intermediate risk	<100 mg/dL	<130 mg/dL	≥90 mg/dL
High risk (FH, multiple risk factors, 亚临床动脉粥样硬化亚临床动脉粥样硬化是指虽然存在斑块，但尚未引起任何症状或事件。.)	<70 mg/dL	<100 mg/dL	≥70 mg/dL
Established ASCVD at very high risk	<55 毫克/分升	<85 mg/dL	≥60 mg/dL

Table 4. LDL-C and non-HDL-C goals from the 2026 ACC/AHA multisociety 血脂异常血脂异常是血液中脂肪成分不健康的一种医学术语。它可能意味着高低密度脂蛋白、高甘油三酯、低高密度脂蛋白，或者是这些情况的某种组合。. guideline [32], with apoB thresholds for considering intensification of lipid-lowering therapy from the 2024 National Lipid Association expert consensus [33]. These are context-dependent thresholds, not universal grades. The 2019 ESC/EAS guideline gives corresponding apoB goals of <100, <80, and <65 mg/dL for moderate, high, and very-high risk [31]; note from Table 3 that these pairings are not percentile-equivalent to their LDL-C counterparts.

Lp(a) sits outside this structure and should be handled separately. Measure it at least once in a lifetime; a level of 125 nmol/L or above — approximately 50 mg/dL — is risk-enhancing, and roughly 250 nmol/L is associated with approximately a twofold higher long-term risk [32]. Mass and molar units are not exactly interchangeable, because apo(a) isoform size varies between individuals.

Two calibrations are worth holding alongside the guideline numbers, with care about what they do and do not imply. Cord-blood LDL-C in term newborns is typically reported in the range of roughly 20–45 mg/dL, with meaningful variation between cohorts and assay methods [40]. And in the ARICARIC（动脉粥样硬化风险社区研究）自20世纪80年代末以来一直在对数千名美国成年人进行追踪调查。. cohort, Black carriers of rare PCSK9 nonsense variants had approximately 28% lower LDL-C and 88% lower 冠心病冠心病是因动脉粥样硬化斑块积聚导致为心肌供血的动脉狭窄或阻塞，它是全球心脏病发作和心脏性死亡的主要原因。. risk over 15 years [30]. That Mendelian association reflects lifelong exposure and should not be read as an expected treatment effect from starting a drug in midlife, nor as establishing a universal LDL-C target of 50–70 mg/dL.

7. Cumulative ApoB Exposure as a Framework

累积暴露累积暴露量是指你的一生中动脉所浸泡的有害胆固醇颗粒的总量——即浓度乘以时间。. to apoB-containing lipoproteins is a biologically coherent framework for understanding lifetime risk. It is not, however, a prospectively validated clinical unit or risk equation, and established plaque can stabilize or regress under treatment [36]. What follows should be read as a way of organizing the evidence, not as a calculator.

Three lines of evidence support the framework. Naturally occurring variants that lower LDL-C by 38.7 mg/dL from birth are associated with roughly 54.5% lower coronary heart disease risk — approximately three times the reduction observed in trials of therapy begun in later life [21]. This is an association produced by lifelong genetic exposure, not a direct estimate of the effect of starting medication today. Second, cumulative LDL-C exposure from young adulthood through middle age predicts later coronary events independently of the most recent measurement [29]. Third, in the FOURIER open-label extension, patients originally randomized to evolocumab retained lower event and cardiovascular death rates than those whose treatment began about two years later [8]; this is consistent with benefits of earlier treatment, though extension-phase comparisons cannot prove a fixed, irreversible penalty from delay.

Scenario (ages 20–70)	ApoB trajectory (mg/dL)	Cumulative exposure (mg/dL·y)	Reduction vs untreated
未处理的	100 throughout	5,000	—
Therapy from age 50	100 to age 50, then 60	4,200	16%
Therapy from age 40	100 to age 40, then 60	3,800	24%
Therapy from age 30	100 to age 30, then 60	3,400	32%
Intensive from age 30	100 to age 30, then 40	2,600	48%
Genetically low lifelong	60 throughout	3,000	40%

Table 5. Illustrative cumulative-exposure arithmetic. These are exposure integrals under hypothetical trajectories, not validated risk equations, and they carry no implied event rates. They are included to show the structure of the problem — that timing and duration enter the exposure calculation as directly as level does.

VESALIUS-CV should be set against that framework qualitatively rather than arithmetically. The trial created substantial separation in both LDL-C and apoB over a median 4.6 years and reduced cardiovascular events [1]. It demonstrates that intensive lowering initiated later in life still produces meaningful benefit. It does not license scaling that treatment effect linearly against a hypothetical fifty-year exposure ledger, and LDL-C年数LDL-C-years is a cumulative exposure metric that multiplies a person's LDL cholesterol level by the number of years they have carried it, capturing lifetime arterial burden rather than a single snapshot; a threshold of roughly 5,000 mg/dL-years is used to identify the point at which clinically significant plaque risk accumulates. and apoB-years are not interchangeable units in any case.

The framework offers one hypothesis about the delayed curve separation in the diabetes subgroup: when advanced plaque burden is lower, benefit may depend more heavily on preventing further cumulative exposure. The subgroup analysis cannot establish this mechanism.

8. Is Evolocumab Better Than a Statin?

The question separates into distinct claims, some of which are settled and some of which are not.

Dimension	他汀类药物	依洛尤单抗
Benefit per 38.7 mg/dL LDL-C removed	RR ~0.79 per mmol/L across 27 trials [9]	No randomized head-to-head comparison; meta-regression finds broadly similar reductions per mmol/L across LDL-receptor-mediated therapies [19]
Magnitude achievable	30–55% LDL-C reduction; effect plateaus with dose	55–60% added to maximal statin [1]; ~57% as monotherapy with diet alone [34]
ApoB reduction in VESALIUS-CV	—	44% on top of existing therapy [1]
脂蛋白(a)	No reduction; may rise slightly	20–27% reduction [5]
New-onset diabetes	Small excess, concentrated in those already near threshold [37]	No signal [1]
肌肉症状	Frequently reported during statin treatment and a common reason for discontinuation, although the excess of muscle symptoms pharmacologically attributable to statins is small in blinded trials [39]	Tolerated in statin-intolerant patients [35]
Anti-inflammatory effect	Lowers hsCRP substantially	Minimal effect on hsCRP
Monotherapy outcomes evidence	Multiple primary-prevention trials [11,13–17]	None; VESALIUS-CV non-statin subgroup HR ~0.87–0.88 with CI crossing 1, underpowered [1]
Route, cost, access	Oral, generic, inexpensive	Injectable every 2 weeks, expensive, often requires prior authorization

Table 6. Statins and evolocumab across the dimensions on which they differ.

There is no randomized head-to-head evidence that evolocumab produces greater event reduction than a statin for the same apoB reduction. Its practical advantage is the large additional LDL-C and apoB reduction it can achieve when background therapy is insufficient [1,19].

Lp(a) is the one axis on which the two classes clearly differ pharmacologically. Elevated Lp(a) supports more intensive overall risk reduction [32]. However, cardiovascular benefit from selectively lowering Lp(a) has not yet been established in an outcomes trial. In the VESALIUS-CV Lp(a) analysis, higher baseline Lp(a) remained associated with higher 绝对风险绝对风险是指某事发生在您身上的真实几率，以百分比表示。如果您在未来十年内患心脏病的绝对风险是 12%，这意味着每 100 个与您相似的人中，大约有 12 人会患病。., but no statistically significant treatment interaction demonstrated that the modest Lp(a) reduction mediated the benefit [5].

9. What It Adds on Top of a Statin

Statins upregulate hepatic 低密度脂蛋白受体LDL受体是肝细胞上的一个对接端口，它从血液中抓取LDL颗粒并将其拉入体内进行分解。. but also increase PCSK9, which directs a fraction of those receptors to degradation. This is one reason statin 剂量-反应剂量-效应关系意味着某事物的剂量增加会以稳定的梯度产生更大的效应。. curves flatten. Blocking PCSK9 removes that constraint, which is why the reductions are largely additive.

VESALIUS-CV quantifies the residual. Its participants were, by conventional standards, treated: approximately 87% on a statin, 68% at high intensity, 19% on ezetimibe. They still had a median LDL-C of 122 mg/dL and apoB of 102 mg/dL [1]. Adding evolocumab lowered apoB by 44% and produced a 25% reduction in three-point MACE over 4.6 years, with five-year NNTs of 56 and 36 for the three- and four-point endpoints — or approximately 55 total events per 1,000 treated once recurrent events are counted [1,3].

Across randomized trial populations, cardiovascular benefit remained consistent down to achieved LDL-C levels around 20–30 mg/dL, with no observed offsetting safety signal during the available trial follow-up [20]. What changes as achieved levels fall is chiefly the absolute benefit, since the 剩余风险残余风险是指在采取了常规干预措施（如治疗胆固醇、控制血压、戒烟）之后依然存在的风险。. available to be reduced is smaller.

10. What Primary Prevention Should Look Like Now

1. Measure the right things. Lp(a) at least once in a lifetime. ApoB when triglycerides exceed 200 mg/dL, in diabetes or 胰岛素胰岛素是由胰腺产生的一种激素。它的主要功能是让血液中的糖分进入细胞以提供能量。. resistance, and when achieved LDL-C is below 70 mg/dL — the settings in which LDL-C most often underestimates particle burden [32,33].
2. Stratify with imaging where it will change management. A coronary 钙化积分钙化积分（冠状动脉钙化积分）是通过CT扫描得出的一项数值，用于量化冠状动脉内钙化斑块的总量；得分为零表示未检测到钙化斑块，而较高的得分则反映出更重的斑块负荷以及升高的心血管疾病风险。. of 100 or more, or a stenosis of 50% or more, placed a VESALIUS-CV participant outside the no-known-atherosclerosis stratum [2]. The 2026 guideline recommends selective rather than universal calcium scoring [32].
3. Treat earlier where risk is established. The 2026 guideline frames this as reducing lifelong exposure to atherogenic lipoproteins, with pharmacotherapy considered in young adulthood at LDL-C of 160 mg/dL or above, or with a strong 家族史家族史是指您的近亲是否患过心脏病，以及他们发病时的年龄有多大。. [32].
4. Set goals by risk tier and confirm with apoB where indicated: LDL-C below 100 for borderline or intermediate risk, below 70 for high risk, below 55 for very-high-risk established disease [32].
5. Escalate according to circumstance. Depending on baseline risk, LDL-C response, statin tolerance, comorbidity, cost, and access, additional therapy may include ezetimibe, 贝普多酸苯培酸是一种降胆固醇药丸，在肝脏中发挥作用，其作用点略早于他汀类药物的作用机制。., or a PCSK9-directed agent. VESALIUS-CV supports considering PCSK9 therapy earlier in selected high-risk patients resembling the trial population; it does not establish routine use in all people with diabetes or in average-risk primary prevention [1,2].
6. Treat duration as a variable, not a constant. The genetic and cumulative-exposure evidence indicates that when treatment begins matters, not only how far the level falls [21,29] — while recognizing that this evidence is associational and cannot be converted into a treatment-effect estimate.

11. 限制

• VESALIUS-CV was not a mediation trial. It cannot establish that prevented events were attributable specifically to apoB lowering rather than to correlated effects of the intervention.
• The framing of “no prior events” is imprecise. Two-thirds of participants had documented atherosclerosis and 45% had coronary disease; only about a third represented high-risk primary prevention without qualifying atherosclerosis [1,2].
• Patients classified as having no known significant atherosclerosis were not systematically imaged to exclude plaque [2].
• The diabetes subgroup establishes benefit in high-risk primary prevention. It does not establish benefit in an average-risk person without diabetes, atherosclerosis, or substantially elevated apoB [2].
• The trial population was 93% White, limiting generalization [1].
• Mortality findings fall outside the hierarchical testing sequence and are exploratory [1,6].
• The non-statin subgroup was too small to demonstrate outcome benefit from evolocumab monotherapy; absence of significance in an underpowered subgroup is not evidence of absence [1].
• The per-mmol/L standardization in Section 4 assumes log-linearity and does not adjust for duration, population risk, or endpoint composition.
• The cumulative-exposure arithmetic in Table 5 is illustrative. “ApoB-years” is not a validated clinical unit, and LDL-C-years and apoB-years are not interchangeable.

12. 结论

VESALIUS-CV extends intensive lipid lowering upstream of the first major event and shows that the exposure-response relationship governing atherosclerotic risk does not begin at the moment of an infarction [1,2]. Its effect sizes are broadly consistent with what the statin literature predicts for the same reduction in atherogenic lipoproteins, which supports — without proving — a shared lipid-mediated mechanism [19].

Cumulative exposure to apoB-containing lipoproteins remains the most coherent framework for organizing this evidence, provided it is presented as a framework. LDL-C is a serviceable proxy and the metric on which nearly all outcome evidence rests, but it may underestimate atherogenic particle burden in clinically important groups, including patients with diabetes, insulin resistance, elevated triglycerides, statin treatment, or very low achieved LDL-C. The workable synthesis is to treat LDL-C as the operational target because that is where the trial evidence lives, and to use apoB selectively as a check on whether the LDL-C value is representing particle burden faithfully [32,33].

VESALIUS-CV establishes that adding evolocumab to optimized lipid-lowering therapy reduces first major cardiovascular events in selected high-risk patients without prior myocardial infarction or stroke [1]. Most participants with documented atherosclerosis or prior PCI would nevertheless ordinarily be classified as secondary-prevention patients; the 3,655-patient diabetes subgroup without known significant atherosclerosis provides the clearest direct primary-prevention evidence [2]. The trial demonstrated a significant 36% reduction in myocardial infarction, whereas the reduction in ischemic stroke was a nonsignificant trend [1]. It does not establish routine evolocumab treatment for average-risk primary prevention, effectiveness as monotherapy, or a validated cumulative-exposure treatment algorithm.

参考文献

1. Bohula EA, Marston NA, Bhatia AK, et al; VESALIUS-CV Investigators. Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med. 2026;394(2):117–127. doi:10.1056/NEJMoa2514428
2. Marston NA, Bohula EA, Bhatia AK, et al; VESALIUS-CV Investigators. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial. JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277
3. Nicolau JC, Murphy SA, Giugliano RP, et al. Cumulative benefit with evolocumab in patients with no prior myocardial infarction or stroke in the VESALIUS-CV study. J Am Coll Cardiol. 2026 Aug 28:S0735-1097(26)07440-1. doi:10.1016/j.jacc.2026.08.015. PMID: 42663360
4. Bergmark BA, Bohula EA, Marston NA, et al. Evolocumab in patients with prior percutaneous coronary intervention and no prior MI: results from the VESALIUS-CV trial. Circulation. 2026;154(1):28–36. doi:10.1161/CIRCULATIONAHA.126.080616
5. Monguillon V, Marston NA, Bohula EA, et al. Lipoprotein(a) levels, risk of cardiovascular events, and benefit of evolocumab: findings from the VESALIUS-CV trial. Circulation. 2026;153(25):1960–1968. doi:10.1161/CIRCULATIONAHA.126.080999
6. Giugliano RP, Bohula EA, Bellavia A, et al. Effects of evolocumab on mortality outcomes in patients without previous myocardial infarction or stroke: a prespecified analysis of the VESALIUS-CV randomized clinical trial. Circulation. 2026. doi:10.1161/CIRCULATIONAHA.126.082436
7. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
8. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE). Circulation. 2022;146(15):1109–1119.
9. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
10. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N Engl J Med. 1995;333(20):1301–1307.
12. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of the West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073–1080.
13. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: AFCAPS/TexCAPS. JAMA. 1998;279(20):1615–1622.
14. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations (ASCOT-LLA). Lancet. 2003;361(9364):1149–1158.
15. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes (CARDS). Lancet. 2004;364(9435):685–696.
16. Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
17. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–2031.
18. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation. 2019;140(12):992–1003. doi:10.1161/CIRCULATIONAHA.118.039415
19. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.
20. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3(9):823–828.
21. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–2639.
22. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472.
23. Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364–373.
24. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–2330.
25. Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.
26. Sayed A, Peterson ED, Virani SS, et al. Individual variation in the distribution of apolipoprotein B levels across the spectrum of LDL-C or non-HDL-C levels. JAMA Cardiol. 2024;9(8):741–747. doi:10.1001/jamacardio.2024.1310
27. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439–1450.
28. Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis. JAMA Cardiol. 2022;7(3):250–256.
29. Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 2021;6(12):1406–1413.
30. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272.
31. Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
32. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. doi:10.1161/CIR.0000000000001423
33. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647–e663. doi:10.1016/j.jacl.2024.08.013
34. Blom DJ, Hala T, Bolognese M, et al; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–1819.
35. Nissen SE, Stroes E, Dent-Acosta RE, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. JAMA. 2016;315(15):1580–1590.
36. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373–2384.
37. Cholesterol Treatment Trialists’ Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia: individual participant meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306–319.
38. Kalra DK, Ray KK, Bajaj A, et al. Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: a meta-analysis. J Clin Lipidol. 2026;20(4):738–749. doi:10.1016/j.jacl.2026.02.006
39. Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–845. doi:10.1016/S0140-6736(22)01545-8
40. Fetal and neonatal cholesterol metabolism. In: Feingold KR, Ahmed SF, Blackman MR, et al., eds. Endotext. South Dartmouth, MA: MDText.com, Inc.; updated 2023. NCBI Bookshelf NBK395580.

This paper is educational content prepared for curingheartdisease.com and is not medical advice. Treatment decisions should be made with a qualified clinician.